Delving into the Latest Updates on Diroleuton with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(8Z,11Z,14Z)-Icosatrienoic acid, (Z,Z,Z)-8,11,14-Eicosatrienoic acid, (Z,Z,Z)-8,11,14-Icosatrienoate

+ [27]

Target

IL-10

Action

inhibitors

Mechanism

IL-10 inhibitors(Interleukin-10 inhibitors)

Therapeutic Areas

Skin and Musculoskeletal Diseases

Active Indication

Acne Vulgaris

Inactive Indication

Alzheimer DiseaseMild Atopic DermatitisModerate Atopic Dermatitis+ [3]

Originator Organization

Suntory Beverage & Food Ltd.

Active Organization

Suntory Beverage & Food Ltd.

Inactive Organization

Dignity Sciences Ltd.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC20H34O2

InChIKeyHOBAELRKJCKHQD-QNEBEIHSSA-N

CAS Registry1783-84-2

The purpose of this study is to determine whether orally administered DS107 (1g and 2g doses) is effective in the treatment of moderate to severe atopic dermatitis.
Oral DS107 capsules will be administered for 8 weeks and will be compared against placebo.
The study will enroll approximately 300 subjects.

Start Date01 Jan 2017

Sponsor / Collaborator

Dignity Sciences Ltd.

100 Clinical Results associated with Diroleuton

Login to view more data

100 Translational Medicine associated with Diroleuton

Login to view more data

100 Patents (Medical) associated with Diroleuton

Login to view more data

13,804

Literatures (Medical) associated with Diroleuton

01 Apr 2025·Brain Research

Impact of preconceptional intermittent fasting on reflex ontogenesis, physical and somatic development of the offspring of Wistar rats

Article

Author: Gomes Dutra, Larissa Maria ; de Souza Aquino, Jailane ; Barbosa Soares, Juliana Késsia ; Tribuzy de Magalhães Cordeiro, Angela Maria ; Vasconcelos de Araújo, Alana Natalícia ; Almeida Gonçalves, Stephenson Andriola ; Dantas, Bruno Silva ; Alves, Adriano Francisco

BACKGROUNDIntermittent fasting (IF) has health benefits; however, little is known about its effects on the offspring when practiced by dams in the preconception period. The aim of the study was to evaluate the impact of IF during the preconception period on physical and somatic parameters, as well as on the reflex ontogenesis of Wistar rat offspring.METHODSThe female rats were randomized into two groups: control (CG) and intermittent fasting group (IF) submitted to a feed restriction of 16 h for four weeks during the preconception period. Reproductive performance, body weight, and energy intake were evaluated in dams. Reflex ontogeny, physical and somatic development, brain fatty acids and the brain histology were evaluated in the offspring.RESULTSIF did not change the reproductive performance or weight of dams during the preconception period. An acceleration of vibrissae placing and negative geotaxis parameters of reflex ontogenesis was observed, as well as anticipation of the following physical development indicators: ear unfolding, an eruption of upper incisor teeth, and inferior teeth in the IF offspring. Although the nervous tissue did not present histological changes, the content of some brain fatty acids was found in greater amounts in the IF offspring such as dihomo-γ-linolenic acid (0.66 ± 0.01 %) and eicotrienoic acid (0.58 ± 0.03 %).CONCLUSIONIF during preconception did not change the body weight or reproductive performance of the dams, and promoted beneficial effects on the neurodevelopment of the offspring in the early life.

01 Apr 2025·Aquaculture

Effects of dietary zinc on growth, bone-related genes expression and skeletal anomalies in gilthead seabream (Sparus aurata) larvae

Author: Sivagurunathan, U. ; Dominguez, David ; Tseng, Yiyen ; Izquierdo, Marisol ; Philip, Antony Jesu Prabhu

Zinc (Zn) is one of the essential nutrients required for growth and bone development in all vertebrates.Zn deficiency has been related to demineralization of bones and low growth in fish.The present study was conducted to determine the role of dietary Zn levels on growth, bone mineralization, gene expression and skeletal anomalies during early developmental stages of gilthead seabream (Sparus aurata).For that purpose, larvae were fed with six microdiets containing different levels of Zn: 79, 98, 110, 130, 150, and 248 mg Zn/kg diets, resp.After 16 days of feeding, larvae fed diets with110 and 130 mg Zn/kg showed better growth and mineralization of vertebrae, along with a lower incidence of skeletal anomalies compared to larvae fed with other diets.Moreover, the expression of bmp2, opn and oc was linearly related to mineralization of vertebrae.On the contrary, larvae fed diets non-supplemented with Zn (79 mg Zn/kg diet), showed an increase in the TBARS value, reduced growth, and a high incidence of severe skeletal anomalies denoting a deficiency in Zn.Besides, the highest dietary Zn levels (248 mg Zn/kg diet) also increased TBARS value and reduced larval growth.These results suggested that dietary Zn levels up to 110 mg/kg would be required by seabream larvae (36 dph) to promote growth, bone mineralization, protection from oxidation and prevent the prevalence of skeletal anomalies, whereas symptoms of Zn deficiency and excess were resp. found at 79 and 248 mg Zn/kg diet.

01 Apr 2025·Meat Science

Flax seed meal improved the meat tenderness, nutritional value of fatty acids, and catalase activity of Hu lambs

Article

Author: Zhang, Hangyu ; Guo, Long ; Tang, Jianyun ; Yue, Xiangpeng ; Hou, Pengxia ; Zhang, Xueying ; Zhang, Wei ; Wang, Xinji ; Li, Fadi ; Li, Fei

Thirty male Hu lambs (38.95 ± 3.87 kg; 6 months old) were randomly assigned to two groups: (1) SBM (a basal diet with soybean meal) and (2) FSM (a diet replacing 10 % soybean meal with 10 % flax seed meal) to evaluate their effects on Hu lamb production and slaughter performance, meat quality, muscle fatty acid composition, and antioxidant capacity. The production and slaughter performance, as well as the amino acid composition in muscle were not different between groups. The FSM decreased muscle shear-force (P = 0.019), the pH _24h (P = 0.002), and the cooking loss (P = 0.008). The b* (yellowness, P = 0.039) and the a* (redness, P = 0.008) of the FSM were lower than those of the SBM. FSM group reduced muscle hardness (P = 0.004), gumminess (P = 0.009), chewiness (P = 0.007), and the diameter of muscle fibers (P < 0.05). A significant increase of total n-3 polyunsaturated fatty acids (P = 0.001), the content of α-linolenic acid (ALA, P = 0.003), homo-gamma-linolenic acid (P = 0.034), docosadienoic acid (P = 0.001), and docosahexaenoic acid (DHA, P = 0.003) was obtained in the FSM group. The CAT activity of FSM was significantly higher than that of SBM (P < 0.05). In conclusion, compared with the SBM, the FSM could effectively improve the meat tenderness, the content of ALA and DHA, and the catalase activity in muscle of Hu lambs.

100 Deals associated with Diroleuton

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Diroleuton	-	DB00154

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Moderate Atopic Dermatitis	Phase 3	Canada	Dignity Sciences Ltd.	01 Jan 2015
Moderate Atopic Dermatitis	Phase 3	United States	Dignity Sciences Ltd.	01 Jan 2015
Severe Atopic Dermatitis	Phase 3	Canada	Dignity Sciences Ltd.	01 Jan 2015
Severe Atopic Dermatitis	Phase 3	United States	Dignity Sciences Ltd.	01 Jan 2015
Acne Vulgaris	Phase 2	-	Suntory Beverage & Food Ltd.	-
Mild Atopic Dermatitis	Preclinical	Canada	Dignity Sciences Ltd.	01 Dec 2016
Moderate Atopic Dermatitis	Preclinical	Canada	Dignity Sciences Ltd.	01 Jan 2015
Moderate Atopic Dermatitis	Preclinical	United States	Dignity Sciences Ltd.	01 Jan 2015
Severe Atopic Dermatitis	Preclinical	Canada	Dignity Sciences Ltd.	01 Jan 2015
Severe Atopic Dermatitis	Preclinical	United States	Dignity Sciences Ltd.	01 Jan 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02864498 (CTgov)	Phase 2	Dermatitis, Atopic	321	DS107 (1g DS107)	ynccpkjmsi(nnjjpkgval) = jrxdkaxucv ecbvhciabr (builbimhwu, dazkxikcuf - ftnkiegpcl) View more	-	10 Oct 2022
				DS107 (2g DS107)	ynccpkjmsi(nnjjpkgval) = vmdpnaszco ecbvhciabr (builbimhwu, lbdmvcuwft - kjqcdyovcb) View more
NCT02925793 (CTgov)	Phase 2	Alzheimer Disease \| Moderate Atopic Dermatitis \| Mild Atopic Dermatitis	327	Vehicle cream (Vehicle Cream)	bhzsjpisop(hydcgfjvdx) = bnfqgdsrco wrkadwktjs (lywuxkeyvb, darbszxrph - exiohidtow) View more	-	07 Oct 2022
				DS107 (1% DS107 Cream)	bhzsjpisop(hydcgfjvdx) = fdghurzcks wrkadwktjs (lywuxkeyvb, wbpngbfohl - azdhqdnlbm) View more
NCT02211417 (CTgov)	Phase 2	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	102	Placebo (Placebo)	nbxnqqwqyy(reuptxccij) = oevprhxoxw oywgemzawi (cugdxmxpym, kiwbpdyjrx - cefjuhbmas) View more	-	07 Oct 2022
				Oral DS107 (Oral DS107 2g)	nbxnqqwqyy(reuptxccij) = vewajesnmz oywgemzawi (cugdxmxpym, lxnkezastz - gnvocamccl) View more
NCT03817190 (CTgov)	Phase 2	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	219	Placebo	kekvggcmaa(cbatnwogrd) = nddkwsqcgo lznnqbpkpg (kxnhhtdmxh, ttlhtpmjpq - gtweibbjuf) View more	-	06 May 2022
ISC2020	Not Applicable	Acute Ischemic Stroke DHLA \| AA \| EPA ... View more	111	Dihomo-gamma-linolenic acid (DHLA)	hslnxexsmq(efwjtzdnnx) = woxiztmuhx baooyukyyl (wuzorecmai ) View more	-	01 Feb 2020
				Control group (without DHLA)	hslnxexsmq(efwjtzdnnx) = sfxifztkhu baooyukyyl (wuzorecmai ) View more